NO315856B1 - Vandig lösning av delvis renset faktor IX, samt fremgangsmåte for å rense faktor IX fra andre proteiner og makromolekyler i en lösning medslike - Google Patents

Vandig lösning av delvis renset faktor IX, samt fremgangsmåte for å rense faktor IX fra andre proteiner og makromolekyler i en lösning medslike Download PDF

Info

Publication number: NO315856B1
Authority: NO; Norway
Prior art keywords: factor; solution; salt; concentration; purification
Prior art date: 1991-03-01

Application number

NO19933114A

Other languages

English (en)

Norwegian (no)

Other versions

NO933114L (no

NO933114D0 (no

Inventor

Chin C Huang

Takashi Enkoji

Laura Ho

Richard R Kleszynski

Richard L Weeks

Fred Feldman

Original Assignee

Aventis Behring Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-01

Filing date

1993-09-01

Publication date

2003-11-03

1993-09-01 Application filed by Aventis Behring Llc filed Critical Aventis Behring Llc

1993-09-01 Publication of NO933114L publication Critical patent/NO933114L/no

1993-09-01 Publication of NO933114D0 publication Critical patent/NO933114D0/no

2003-11-03 Publication of NO315856B1 publication Critical patent/NO315856B1/no

Links

102100022641 Coagulation factor IX Human genes 0.000 title claims description 346
229960004222 factor ix Drugs 0.000 title claims description 345
108010076282 Factor IX Proteins 0.000 title claims description 339
238000000034 method Methods 0.000 title claims description 111
108090000623 proteins and genes Proteins 0.000 title claims description 62
102000004169 proteins and genes Human genes 0.000 title claims description 60
239000000243 solution Substances 0.000 title claims description 59
239000007864 aqueous solution Substances 0.000 title claims description 10
229920002521 macromolecule Polymers 0.000 title claims description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 115
150000003839 salts Chemical class 0.000 claims description 108
239000011780 sodium chloride Substances 0.000 claims description 60
108010048049 Factor IXa Proteins 0.000 claims description 57
230000000694 effects Effects 0.000 claims description 57
238000000746 purification Methods 0.000 claims description 52
238000002360 preparation method Methods 0.000 claims description 44
210000002381 plasma Anatomy 0.000 claims description 34
238000000926 separation method Methods 0.000 claims description 32
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 28
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 28
239000003114 blood coagulation factor Substances 0.000 claims description 28
108091005804 Peptidases Proteins 0.000 claims description 24
239000004365 Protease Substances 0.000 claims description 24
238000004587 chromatography analysis Methods 0.000 claims description 22
230000004913 activation Effects 0.000 claims description 21
238000001994 activation Methods 0.000 claims description 21
108090000765 processed proteins & peptides Proteins 0.000 claims description 20
230000001225 therapeutic effect Effects 0.000 claims description 20
230000015556 catabolic process Effects 0.000 claims description 19
238000006731 degradation reaction Methods 0.000 claims description 19
238000003860 storage Methods 0.000 claims description 18
102000004196 processed proteins & peptides Human genes 0.000 claims description 17
239000011347 resin Substances 0.000 claims description 17
229920005989 resin Polymers 0.000 claims description 17
102000035195 Peptidases Human genes 0.000 claims description 16
239000003957 anion exchange resin Substances 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 12
230000002411 adverse Effects 0.000 claims description 11
238000000502 dialysis Methods 0.000 claims description 11
238000001179 sorption measurement Methods 0.000 claims description 10
239000012266 salt solution Substances 0.000 claims description 9
230000001419 dependent effect Effects 0.000 claims description 8
208000009429 hemophilia B Diseases 0.000 claims description 8
238000001556 precipitation Methods 0.000 claims description 8
235000019168 vitamin K Nutrition 0.000 claims description 8
239000011712 vitamin K Substances 0.000 claims description 8
229930003448 Vitamin K Natural products 0.000 claims description 7
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 7
230000002829 reductive effect Effects 0.000 claims description 7
150000003721 vitamin K derivatives Chemical class 0.000 claims description 7
229940046010 vitamin k Drugs 0.000 claims description 7
230000007012 clinical effect Effects 0.000 claims description 6
238000005194 fractionation Methods 0.000 claims description 6
229920000669 heparin Polymers 0.000 claims description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
238000011026 diafiltration Methods 0.000 claims description 5
229960002897 heparin Drugs 0.000 claims description 5
230000002427 irreversible effect Effects 0.000 claims description 5
238000011287 therapeutic dose Methods 0.000 claims description 5
241000700605 Viruses Species 0.000 claims description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
235000011130 ammonium sulphate Nutrition 0.000 claims description 4
230000008859 change Effects 0.000 claims description 4
238000004925 denaturation Methods 0.000 claims description 4
230000036425 denaturation Effects 0.000 claims description 4
238000004255 ion exchange chromatography Methods 0.000 claims description 4
102000004506 Blood Proteins Human genes 0.000 claims description 3
108010017384 Blood Proteins Proteins 0.000 claims description 3
159000000009 barium salts Chemical class 0.000 claims description 3
230000003197 catalytic effect Effects 0.000 claims description 3
244000005700 microbiome Species 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
238000005119 centrifugation Methods 0.000 claims description 2
238000011146 sterile filtration Methods 0.000 claims description 2
238000000108 ultra-filtration Methods 0.000 claims description 2
230000008021 deposition Effects 0.000 claims 2
238000001042 affinity chromatography Methods 0.000 claims 1
238000000909 electrodialysis Methods 0.000 claims 1
230000036039 immunity Effects 0.000 claims 1
239000006193 liquid solution Substances 0.000 claims 1
239000008176 lyophilized powder Substances 0.000 claims 1
235000002639 sodium chloride Nutrition 0.000 description 153
235000018102 proteins Nutrition 0.000 description 52
238000003556 assay Methods 0.000 description 26
239000012141 concentrate Substances 0.000 description 25
239000000047 product Substances 0.000 description 25
MELCWEWUZODSIS-UHFFFAOYSA-N 2-[2-(diethylamino)ethoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOCCN(CC)CC MELCWEWUZODSIS-UHFFFAOYSA-N 0.000 description 24
229920005654 Sephadex Polymers 0.000 description 19
239000012507 Sephadex™ Substances 0.000 description 19
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
239000000499 gel Substances 0.000 description 17
238000005571 anion exchange chromatography Methods 0.000 description 15
108010094028 Prothrombin Proteins 0.000 description 14
102100027378 Prothrombin Human genes 0.000 description 13
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 13
230000017854 proteolysis Effects 0.000 description 13
229940039716 prothrombin Drugs 0.000 description 13
238000012360 testing method Methods 0.000 description 13
230000015271 coagulation Effects 0.000 description 12
238000005345 coagulation Methods 0.000 description 12
238000010828 elution Methods 0.000 description 12
229940024790 prothrombin complex concentrate Drugs 0.000 description 12
239000012467 final product Substances 0.000 description 11
238000001262 western blot Methods 0.000 description 11
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 10
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
108010023321 Factor VII Proteins 0.000 description 9
239000000306 component Substances 0.000 description 9
239000000463 material Substances 0.000 description 9
230000036961 partial effect Effects 0.000 description 9
229910052938 sodium sulfate Inorganic materials 0.000 description 9
235000011152 sodium sulphate Nutrition 0.000 description 9
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000007795 chemical reaction product Substances 0.000 description 8
230000035602 clotting Effects 0.000 description 8
238000011109 contamination Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 7
206010053567 Coagulopathies Diseases 0.000 description 7
108010000499 Thromboplastin Proteins 0.000 description 7
102000002262 Thromboplastin Human genes 0.000 description 7
230000008901 benefit Effects 0.000 description 7
239000000872 buffer Substances 0.000 description 7
230000006378 damage Effects 0.000 description 7
230000008569 process Effects 0.000 description 7
230000001681 protective effect Effects 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
108010062466 Enzyme Precursors Proteins 0.000 description 6
102000010911 Enzyme Precursors Human genes 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
239000000356 contaminant Substances 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
238000007710 freezing Methods 0.000 description 6
230000008014 freezing Effects 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
229910001629 magnesium chloride Inorganic materials 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000001509 sodium citrate Substances 0.000 description 6
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
230000002885 thrombogenetic effect Effects 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
208000031220 Hemophilia Diseases 0.000 description 5
208000009292 Hemophilia A Diseases 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 5
-1 alkaline earth metal salts Chemical class 0.000 description 5
230000000740 bleeding effect Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000000284 extract Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
238000012545 processing Methods 0.000 description 5
230000002797 proteolythic effect Effects 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 4
150000001340 alkali metals Chemical class 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000023555 blood coagulation Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
235000011147 magnesium chloride Nutrition 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000012508 resin bead Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
241000894007 species Species 0.000 description 4
238000013060 ultrafiltration and diafiltration Methods 0.000 description 4
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108010054218 Factor VIII Proteins 0.000 description 3
102000001690 Factor VIII Human genes 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
239000007832 Na2SO4 Substances 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
229940006612 barium citrate Drugs 0.000 description 3
PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 3
239000011575 calcium Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
102000034238 globular proteins Human genes 0.000 description 3
108091005896 globular proteins Proteins 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
208000014674 injury Diseases 0.000 description 3
239000003456 ion exchange resin Substances 0.000 description 3
229920003303 ion-exchange polymer Polymers 0.000 description 3
230000007774 longterm Effects 0.000 description 3
229960003646 lysine Drugs 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
239000011591 potassium Substances 0.000 description 3
239000001103 potassium chloride Substances 0.000 description 3
235000011164 potassium chloride Nutrition 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
239000007858 starting material Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
210000001766 X chromosome Anatomy 0.000 description 2
230000009471 action Effects 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000011324 bead Substances 0.000 description 2
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000007820 coagulation assay Methods 0.000 description 2
238000012777 commercial manufacturing Methods 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
229960000301 factor viii Drugs 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000002439 hemostatic effect Effects 0.000 description 2
229960000027 human factor ix Drugs 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
230000037361 pathway Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical class [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000002792 vascular Effects 0.000 description 2
239000011800 void material Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
MJQHZNBUODTQTK-WKGBVCLCSA-N (2s,3r,4s,5r,6r)-2-[[(1s,3s,4s,5s,8r)-3-[(2s,3r,4s,5s,6r)-2-[[(1s,3r,4s,5s,8r)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5- Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H]2OC[C@@H]1O[C@@H](O[C@@H]1[C@H]([C@H](O[C@H]3[C@H]4OC[C@@H]3O[C@@H](O)[C@H]4O)O[C@H](CO)[C@@H]1O)O)[C@H]2O MJQHZNBUODTQTK-WKGBVCLCSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
229910018626 Al(OH) Inorganic materials 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
108010080865 Factor XII Proteins 0.000 description 1
102000000429 Factor XII Human genes 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000823435 Homo sapiens Coagulation factor IX Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
108010020828 Thrombofax Proteins 0.000 description 1
108091005605 Vitamin K-dependent proteins Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
229910001508 alkali metal halide Inorganic materials 0.000 description 1
229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
229910052936 alkali metal sulfate Inorganic materials 0.000 description 1
229910001615 alkaline earth metal halide Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
229910001626 barium chloride Inorganic materials 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000012503 blood component Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000003575 carbonaceous material Substances 0.000 description 1
UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical group OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
239000012539 chromatography resin Substances 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
229940105774 coagulation factor ix Drugs 0.000 description 1
229940105778 coagulation factor viii Drugs 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
MBGJRCZMULFKGD-UHFFFAOYSA-N fluoro(propan-2-yloxy)phosphinic acid Chemical compound CC(C)OP(O)(F)=O MBGJRCZMULFKGD-UHFFFAOYSA-N 0.000 description 1
238000005187 foaming Methods 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical group OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229910001679 gibbsite Inorganic materials 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
239000012145 high-salt buffer Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940052349 human coagulation factor ix Drugs 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000004137 magnesium phosphate Substances 0.000 description 1
229910000157 magnesium phosphate Inorganic materials 0.000 description 1
229960002261 magnesium phosphate Drugs 0.000 description 1
235000010994 magnesium phosphates Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000001724 microfibril Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
108010012557 prothrombin complex concentrates Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000010008 shearing Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003239 susceptibility assay Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)

NO19933114A 1991-03-01 1993-09-01 Vandig lösning av delvis renset faktor IX, samt fremgangsmåte for å rense faktor IX fra andre proteiner og makromolekyler i en lösning medslike NO315856B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66292791A	1991-03-01	1991-03-01
PCT/US1992/001600 WO1992015324A1 (en)	1991-03-01	1992-02-26	Preparation of factor ix

Publications (3)

Publication Number	Publication Date
NO933114L NO933114L (no)	1993-09-01
NO933114D0 NO933114D0 (no)	1993-09-01
NO315856B1 true NO315856B1 (no)	2003-11-03

Family

ID=24659784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19933114A NO315856B1 (no)	1991-03-01	1993-09-01	Vandig lösning av delvis renset faktor IX, samt fremgangsmåte for å rense faktor IX fra andre proteiner og makromolekyler i en lösning medslike

Country Status (17)

Country	Link
US (3)	US6063909A (fi)
EP (1)	EP0573605B1 (fi)
JP (1)	JP3418621B2 (fi)
AT (1)	ATE195877T1 (fi)
AU (1)	AU671586B2 (fi)
BR (1)	BR9205700A (fi)
CA (1)	CA2105282C (fi)
DE (1)	DE69231401T2 (fi)
DK (1)	DK0573605T3 (fi)
ES (1)	ES2150914T3 (fi)
FI (1)	FI114969B (fi)
GR (1)	GR3034946T3 (fi)
MX (1)	MX9200882A (fi)
NO (1)	NO315856B1 (fi)
RU (1)	RU2142806C1 (fi)
SG (1)	SG48282A1 (fi)
WO (1)	WO1992015324A1 (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69231401T2 (de) *	1991-03-01	2001-02-08	Rhone-Poulenc Rorer International (Holdings) Inc., Greenville	Herstellung von faktor-ix
AU678987B2 (en) *	1992-08-27	1997-06-19	Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis	Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DE19506633A1 (de) *	1995-02-25	1996-08-29	Octapharma Ag	Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
JP3095787B2 (ja) *	1996-10-31	2000-10-10	ロシュダイアグノスティックスゲーエムベーハー	ＩＸａ因子の触媒活性の測定方法
RU2163140C1 (ru) *	2000-07-05	2001-02-20	Гематологический научный центр РАМН	Концентрат фактора ix системы свертывания крови и способ его получения
AU2002226028A1 (en) *	2000-11-14	2002-05-27	Board Of Regents, Unversity Of Texas Systems	Mutant human factor ix with an increased resistance to inhibition by heparin
CA2520970A1 (en) *	2003-04-09	2004-10-28	Robert G. Schaub	Hemophilia treatment by inhalation of coagulation factors
US8158139B2 (en) *	2004-07-12	2012-04-17	Taro Pharmaceuticals North America, Inc.	Topical gel formulation comprising organophosphate insecticide and preparation thereof
WO2006017263A1 (en)	2004-07-12	2006-02-16	Taro Pharmaceutical Industries Ltd.	Topical gel formulation comprising organophosphate insecticide and its preparation thereof
US7560445B2 (en)	2005-07-06	2009-07-14	Taro Pharmaceuticals North America, Inc.	Process for preparing malathion for pharmaceutical use
US9896677B2 (en)	2010-01-18	2018-02-20	Novo Nordisk Health Care Ag	Purification of blood coagulation factors
JP5876868B2 (ja) *	2010-03-30	2016-03-02	オクタファルマ・アーゲー	第ｉｘ凝固因子などのビタミンｋ依存性タンパク質の精製方法
JP6088435B2 (ja)	2010-12-15	2017-03-01	バクスアルタゲーエムベーハー	導電率グラディエントを用いる溶出液収集
US9663553B2 (en)	2014-01-29	2017-05-30	Hemarus Therapeutics Limited	Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU552085A1 (ru) *	1967-06-21	1977-03-30		Средство дл лечени нарушений свертывающей системы крови при тромбоцитопенических состо ни х различного происхождени и дл стимул ции гемоопоэза "эритрофосфатид"
AT368883B (de) *	1980-07-22	1982-11-25	Immuno Ag	Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
DE3045153A1 (de) *	1980-11-29	1982-07-08	Behringwerke Ag, 3550 Marburg	Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
DE3101752A1 (de) *	1981-01-21	1982-08-26	Behringwerke Ag, 3550 Marburg	"verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4447416A (en) *	1982-04-28	1984-05-08	American National Red Cross	Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4379085A (en) *	1982-05-14	1983-04-05	American National Red Cross	Heat stabilization of plasma proteins
US5055557A (en) *	1983-03-04	1991-10-08	Scripps Clinic & Research Foundation	Ultrapurification of factor IX and other vitamin K-dependent proteins
EP0118256B1 (en) *	1983-03-04	1992-05-13	Scripps Clinic And Research Foundation	Immunoadsorbent, and method of recovering vitamin-k dependent protein therewith
US5614500A (en)	1983-03-04	1997-03-25	The Scripps Research Institute	Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
ATE36457T1 (de) *	1983-05-02	1988-09-15	Immuno Ag	Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
JPS60132912A (ja) *	1983-12-21	1985-07-16	Kao Corp	シヤンプ−組成物
ATE74164T1 (de) *	1985-04-22	1992-04-15	Genetics Inst	Herstellung mit hoher leistung des aktivfaktors ix.
US4786726A (en) *	1986-01-06	1988-11-22	Blood Systems, Inc.	Factor IX therapeutic blood product, means and methods of preparing same
FR2600334B1 (fr)	1986-06-23	1989-05-12	Transgene Sa	Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US4725673A (en) *	1986-08-29	1988-02-16	Alpha Therapeutic Corporation	Plasma fraction purification using silica resin bound to a ligand
ES2045167T5 (es)	1987-10-23	1996-07-01	Centre Regional De Transfusion	Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
JPH01258700A (ja)	1988-04-05	1989-10-16	Green Cross Corp:The	血液凝固第４因子の精製方法
DE3826792C1 (fi) *	1988-08-06	1989-07-06	Biotest Pharma Gmbh, 6072 Dreieich, De
US4981952A (en) *	1988-10-04	1991-01-01	Eli Lilly And Company	Method for the purification of vitamin K-dependent proteins
DE3914869C1 (fi) *	1989-05-05	1990-08-09	Biotest Pharma Gmbh, 6072 Dreieich, De
AT402261B (de) *	1991-01-25	1997-03-25	Immuno Ag	Komplex enthaltend den gerinnungsfaktor ix
DE69231401T2 (de) *	1991-03-01	2001-02-08	Rhone-Poulenc Rorer International (Holdings) Inc., Greenville	Herstellung von faktor-ix

1992
- 1992-02-26 DE DE69231401T patent/DE69231401T2/de not_active Expired - Fee Related
- 1992-02-26 WO PCT/US1992/001600 patent/WO1992015324A1/en not_active Ceased
- 1992-02-26 SG SG1996008689A patent/SG48282A1/en unknown
- 1992-02-26 EP EP92908513A patent/EP0573605B1/en not_active Expired - Lifetime
- 1992-02-26 ES ES92908513T patent/ES2150914T3/es not_active Expired - Lifetime
- 1992-02-26 JP JP50823092A patent/JP3418621B2/ja not_active Expired - Fee Related
- 1992-02-26 RU RU93053992A patent/RU2142806C1/ru active
- 1992-02-26 CA CA002105282A patent/CA2105282C/en not_active Expired - Fee Related
- 1992-02-26 AU AU16429/92A patent/AU671586B2/en not_active Ceased
- 1992-02-26 DK DK92908513T patent/DK0573605T3/da active
- 1992-02-26 AT AT92908513T patent/ATE195877T1/de not_active IP Right Cessation
- 1992-02-26 BR BR9205700A patent/BR9205700A/pt not_active Application Discontinuation
- 1992-02-28 MX MX9200882A patent/MX9200882A/es unknown
1993
- 1993-08-03 US US08/101,175 patent/US6063909A/en not_active Expired - Lifetime
- 1993-09-01 FI FI933814A patent/FI114969B/fi not_active IP Right Cessation
- 1993-09-01 NO NO19933114A patent/NO315856B1/no not_active IP Right Cessation
1995
- 1995-06-06 US US08/465,867 patent/US6043215A/en not_active Expired - Lifetime
2000
- 2000-03-13 US US09/524,206 patent/US6280729B1/en not_active Expired - Fee Related
- 2000-11-30 GR GR20000402648T patent/GR3034946T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0573605B1 (en)	2000-08-30
DE69231401T2 (de)	2001-02-08
AU1642992A (en)	1992-10-06
AU671586B2 (en)	1996-09-05
WO1992015324A1 (en)	1992-09-17
ES2150914T3 (es)	2000-12-16
EP0573605A4 (en)	1994-11-23
FI933814L (fi)	1993-09-01
FI933814A0 (fi)	1993-09-01
CA2105282A1 (en)	1992-09-02
DE69231401D1 (de)	2000-10-05
BR9205700A (pt)	1994-06-28
JP3418621B2 (ja)	2003-06-23
CA2105282C (en)	2002-09-24
DK0573605T3 (da)	2001-01-02
US6063909A (en)	2000-05-16
JPH06505494A (ja)	1994-06-23
GR3034946T3 (en)	2001-02-28
US6280729B1 (en)	2001-08-28
EP0573605A1 (en)	1993-12-15
ATE195877T1 (de)	2000-09-15
RU2142806C1 (ru)	1999-12-20
MX9200882A (es)	1992-09-01
FI114969B (fi)	2005-02-15
SG48282A1 (en)	1998-04-17
NO933114L (no)	1993-09-01
NO933114D0 (no)	1993-09-01
US6043215A (en)	2000-03-28

Publication	Publication Date	Title
US5854403A (en)	1998-12-29	Method for isolation of highly pure von Willebrand Factor
US5344918A (en)	1994-09-06	Process for the manufacture of a high-purity activated factor VII concentrate essentially free of vitamin K-dependent factors and factors VIIIC and VIIICAg
DK173859B1 (da)	2001-12-31	Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner
NO315856B1 (no)	2003-11-03	Vandig lösning av delvis renset faktor IX, samt fremgangsmåte for å rense faktor IX fra andre proteiner og makromolekyler i en lösning medslike
WO1996015150A1 (en)	1996-05-23	Process for purifying factor viii
US5824780A (en)	1998-10-20	Activated human factor VIII and method of preparation
EP0907724B1 (en)	2007-03-21	Von willebrand factor multimerase
AU9244998A (en)	1999-04-12	Pharmaceutical substance containing various vitamin k-dependent factors
US6034222A (en)	2000-03-07	Method for the separation of recombinant pro-factor IX from recombinant factor IX
ES2224109T3 (es)	2005-03-01	Procedimiento de preparacion de proteina c humana activada.
JP2886061B2 (ja)	1999-04-26	プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
US11591587B2 (en)	2023-02-28	Process for plasminogen purification starting from human plasma
JP6629744B2 (ja)	2020-01-15	第Ｘａ因子の半減期を延ばす組成物および方法
AU627450B2 (en)	1992-08-27	A method for the purification of factor xiii by affinity chromatography
CA2141642A1 (en)	1995-08-03	Thrombocyte-stabilizing factor ix-fragments, their preparation and use and drugs containing these
Neal et al.	1982	The role of factor VIII in blood coagulation
Carter	2011	Structural-Functional Relationships in the Human Thrombin A-Chain

Legal Events

Date	Code	Title	Description
2005-10-10	MM1K	Lapsed by not paying the annual fees